The hematopoietic cell S/T kinase Pim-1 was originally discovered as a target of murine leukemia provirus integration, and when expressed at increased levels is predisposing to lymphomagenesis. Recently, Pim-1 has been shown to enhance the activities of p100, c-Myb and cdc25a, and in part this might explain reported eects on mitogenesis. In the context of cytokine withdrawal, Pim-1 also can attenuate programmed cell death (PCD). Cytokine withdrawal, however, alters signaling pathways and can complicate the dissection of mitogenic vs apoptotic responses. To better study possible eects of Pim-1 on PCD, a hematopoietic cell model was developed in which proliferation was supported eciently by SCF plus EPO in the absence of endogenous Pim-1 gene expression. This was provided by factor-dependent FDCW2 cells that express endogenous and functional cKit, and were transfected stably with truncated Epo receptor form mutated at a Y343 STAT5 binding site. In proliferating cells, exogenously expressed Pim-1 was observed to eciently inhibit PCD as induced by either Co 60 or adriamycin, and the dose-dependent nature of this eect was established in several independent clones. By comparison, eects of exogenous Pim-1 on mitogenesis were nominal. In addition, in cell fractionation studies an estimated 25% of M r 34 000 Pim-1 (but not M r 44 000 Pim-1) was present in nuclear extracts. Thus, Pim-1 eciently buers hematopoietic progenitor cells against death as induced by several clinically important apoptotic agents, and may directly target nuclear eectors. Oncogene (2000) 19, 3684 ± 3692.
Introduction
Pim-1 is a S/T kinase that is structurally related most closely in its catalytic domain to cGMP-dependent and phosphorylase kinases (Selten et al., 1986) . Pim-1 expression is relatively high in cells of hematolymphoid origin, and is induced primarily in response to cytokines which act via a subset of Janus kinaselinked type 1 receptors (including those for IL-2, IL-3, IL-6, IL-9, Epo, C-CSF, GM-CSF, Tpo and prolactin) (Buckley et al., 1995; Dautry et al., 1988; Demoulin et al., 1999; Lilly et al., 1992; Miura et al., 1994; Nagata and Todokoro, 1995) . Transcript expression has also been characterized in testes (Wingett et al., 1992) , carcinoma-derived keratinocytes, (Stewart and Rice, 1995) and in neuronal cells of the hippocampus (together with pim-2 and -3) (Konietzko et al., 1999) . Originally, Pim-1 was discovered as a common site for murine leukemia provirus integration wherein integration typically within a 3' non-coding exon increases Pim-1 expression (Selten et al., 1986) , and predisposes T cells to transformation (van Lohuizen et al., 1989) . In mice nullizygous for Pim-1, normal hematopoiesis is largely unaected with the exception of a detectable erythroid cell microcytosis (Laird et al., 1993) . In primary cultures of marrow from Pim-17/7 mice, however, diminutions in IL-7-dependent B cell colony formation (Domen et al., 1993a) and IL-3-dependent mast cell proliferation are apparent (Domen et al., 1993b) . More recently, through proviral tagging of Pim-17/7 Em-myc mice, a related Pim-2 protooncogene has also been cloned which likewise is expressed in hematopoietic cells (van der Lugt et al., 1995) . In addition, transcripts from Pim-1 and Pim-2 genes can be translated not only from a canonical AUG codon to yield a M r 34 000 kinases but also from upstream CUG codons to yield a M r 44 000 species (Saris et al., 1991; van der Lugt et al., 1995) .
Despite these advances in understanding Pim kinase structure and expression, the nature of Pim-1's physiological substrates and the pathways they aect have remained relatively obscure. One well-de®ned property is the ability of Pim-1 to act in strong synergy with c-Myc and N-Myc in promoting lymphomagenesis, especially as studied in c-Myc mice expressing Pim-1 from an immunoglobulin heavy chain enhancer cassette (van Lohuizen et al., 1989) . This has led to one model wherein Pim-1 might directly enforce c-Myc pathways, and in transformed Rat1 ®broblasts Pim-1 has been reported to phosphorylate and activate cdc25a (Mochizuki et al., 1999) , a putative c-Myc target gene. Recently, Pim-1 has also been shown to enhance the activity of the hematopoietic transcription factor, c-Myb (Leverson et al., 1998) , and this appears to involve an indirect mechanism whereby Pim-1 phosphorylates the transcriptional co-activator p100. Given the established role of c-Myb as a hematopoietic oncogene (Weston, 1999) this further broadens the oncogenic signi®cance of Pim-1.
A second set of pathways that Pim-1 has been demonstrated to aect are those leading to pro-grammed cell death (PCD). Early studies in EmPim-1  mice documented a survival advantage for CD4   +   /  CD8 + thymocytes exposed to dexamethasone (Moroy et al., 1993) . In addition, recent studies in IL-3-dependent FDCP1 cell lines have demonstrated a Pim-1-dependent inhibition from the apoptosis which occurs following the withdrawal of IL-3 (Lilly and Kraft, 1997) . This includes the inhibition, due to Pim-1 expression, of reactive oxygen species production and of membrane potential decay in mitochondria (Lilly et al., 1999) . Cytokine withdrawal, however, disrupts numerous events which are ongoing in proliferating progenitor cells including cytokine-dependent gene transcription events and mitogenesis per se. In addition, proliferative status can signi®cantly aect sensitivity to clinically applied apoptotic agents (Siu et al., 1999) . Therefore, in the present investigation an FDC cell line model has ®rst been developed in which growth and survival are supported at normal levels in the presence of SCF (via endogenous c-Kit) plus Epo (via an ectopically expressed Epo receptor truncation mutant), but in which endogenous Pim-1 gene expression is not activated. In these FDCER-HY343F cells, the ability of exogenously expressed Pim-1 kinase to inhibit Co 60 and adriamycin induced PCD in proliferating cells was investigated. Pim-1 proved to selectively protect against PCD due to each agent. By comparison, eects of exogenous Pim-1 on mitogenesis were nominal. Finally, M r 34 000 Pim-1 (but not M r 44 000 Pim-1) was also shown to reside in nuclei, and this at least in part may explain Pim-1's ability to modulate several nuclear eectors (Koike et al., 2000; Leverson et al., 1998; Mochizuki et al., 1999; Weston, 1999) .
Results
FDCER-HY343F cells as a model system for studies of Pim-1 effects on genotoxin-induced PCD in proliferating progenitor cells Towards choosing a cell line model for the present investigations of Pim-1 eects on PCD, the expression of endogenous pim transcripts in several IL-3-dependent hematopoietic progenitor cell lines (FDCW2ER-H, 32D, BaF/3) ®rst was assayed (Figure 1 , upper left panel). Pim-1 was expressed at comparable levels in each line. 32D and BaF/3 cells, however, proved to express signi®cantly higher levels of Pim-2 transcripts. To avoid potential complications associated with predicted overlapping activities of Pim-1 and Pim-2 (van der Lugt et al., 1995) , FDCW2 cell lines were used in subsequent studies. In addition, the ectopic expression of Pim-1 in BaF/3 cells somewhat unexpectedly has been observed to promote factor-independent growth (Nosaka et al., 1999) (Joneja and Wojchowski, unpublished result) . Since Pim-1 itself is not transforming (van Lohuizen et al., 1989) this outcome may depend upon a pre-existing mutation or otherwise altered growth regulatory pathway in BaF/3 cells (and in fact has been reported for high-passage FDCP1 cells) (Lilly and Kraft, 1997) . In the FDCW2 cell line model chosen for further investigations, the regulated transcription of the endogenous Pim-1 gene via a stably transfected minimal Epo receptor H form was also con®rmed (Figure 1 , upper right panel). In addition, exposure to ionizing radiation was shown to induce an accumulation of FDCW2 cells at G1/S and G2/M phases of the cell cycle (Figure 1 , lower panels) indicative of wt p53 activity.
Next, in FDCW2 cells stably expressing a minimal H Epo receptor form (i.e., FDCER-HY343 cells), exogenous Pim-1 was expressed (via stable transfection with pEF-Neo-Pim-1) and its ability to inhibit PCD as induced by cytokine withdrawal was assayed. As shown in Figure 2a (upper panel), this activity was con®rmed, and Pim-1 proved to attenuate this pathway to PCD 3 ± 4-fold as compared to parental FDCER-HY343 cells. Also investigated were the combined eects of exposure to either Co 60 or adriamycin and subsequent cytokine withdrawal. In these latter treatment groups, PCD as induced in quiescent cells via these routes likewise was attenuated signi®cantly by ectopically expressed Pim-1 (Figure 2a , center and lower panels). To con®rm the programmed nature of death events, PCD due to cytokine withdrawal also was accessed by¯ow cytometric TUNEL assays (Figure 2b, upper panel) . Finally, in these primary experiments the sustained expression of exogenous Cytokine withdrawal alters the expression of many cytokine response genes (including Pim-1), and cells senesce in G 1 /G 0 . In such cells it is uncertain whether observed eects of ectopically expressed Pim-1 might re¯ect those exerted in growing cells. Also, sensitivities of growing vs quiescent cells to anti-neoplasmic agents can dier markedly. In subsequent experiments therefore, conditions were sought under which factordependent FDCW2 cells could be propagated at normal rates via a route which circumvents endogenous Pim-1 expression. Previously our laboratory has shown that FDCW2 cells express c-Kit, and proliferate at moderate rates in response to SCF (Joneja et al., 1997) . In the present study, c-Kit was discovered to act in mitogenic synergy with an Epo receptor form which retains no cytoplasmic (P)Y residues, and proved to be essentially inactive in growth and survival signaling, i.e., ER-HY343F. This receptor form and its related parent truncation mutant, ER-HY343, are diagrammed in Figure 3 Ectopic expression of Pim-1 in FDCW2-ERH cells inhibits PCD due to cytokine withdrawal alone, and in combination with Co 60 or adriamycin. (a) Pim-1 was expressed in FDCW2-ERH cells using a dicistronic vector, and eects on apoptosis in several contexts of cytokine withdrawal were assayed, including withdrawal of IL-3 (upper panel), exposure to Co 60 followed by cytokine withdrawal (center panel) and exposure to adriamycin followed by cytokine withdrawal (lower panel). For combined treatments, protection against PCD due to Pim-1 expression (closed circles) was compared to that aorded by ectopically expressed Bcl-xL (closed triangles). Here, cell death was assayed based on staining with PI. (b) Pim-1-dependent protection from PCD due to cytokine withdrawal was also assayed by¯ow TUNEL (upper panels). Levels of Pim-1 and Bcl-xL expression in FDCER-HY343 cells (i.e., FDCER-HY343F, Pim-1 and FDCER-HY343-Bcl-xL cells) were assayed by Western blotting following IL-3 withdrawal and subsequent stimulation with Epo for the indicated intervals (lower panels) normally co-propagated by endogenous c-Kit and Epo receptors) (Wu et al., 1995) therefore provided the opportunity to next selectively test in a proliferating, yet essentially Pim-1 null background, possible eects of exogenously expressed Pim-1 on PCD as induced by genotoxic agents, and on mitogenesis.
Pim-1 inhibits Co 60 or adriamycin induced PCD in proliferating FDCER-HY343F cells
Towards testing eects of Pim-1 on genotoxin-induced PCD, FDCER-HY343F cells were electrotransfected with a pEF-Neo-Pim-1 expression vector, and clones which stably expressed exogenous Pim-1 at appreciable levels were identi®ed initially by Northern blotting (see Figure 5 below). Next, the induction of PCD by Co 60 or adriamycin in the representative clonal lines FDCER-HY343F-Pim-1 -c7 and -c11 (vs control Pim-1-de®cient parental cells, each propagated in SCF plus Epo) was assayed. As illustrated in Figure  4 , Pim-1 proved to buer against PCD as induced by each of these agents. For Co 60 (Figure 4 , left panels), induced death events were inhibited on average 2.76-fold (+0.55) as compared to parental Pim-1-de®cient controls. For adriamycin, protection against PCD due to Pim-1 was 2.37-fold (+0.61) (Figure 4 , right panels). Pim-1 expression levels in clones studied in these experiments were assayed in advance by Northern and Western blotting, and inhibition of PCD due to cytokine withdrawal was also con®rmed in all clones studied. The dose-dependent relationship between levels of Pim-1 expression and ability to inhibit apoptosis in response to adriamycin or Co 60 is illustrated in Figures 5 and 6 . In addition, in the course of Western blotting experiments whether Pim-1 occurred only within the cytoplasm was also assessed. Interestingly, an estimated 25% of M r 34 000 Pim-1 (but not M r 44 000 Pim-1) was discovered within nuclear extracts ( Figure 6 , lower panel). Integrity of nuclear (vs cytoplasmic) extracts also was con®rmed by Western blotting with a monoclonal antibody to nucleoporin (data not shown). FDCW2 cell lines also express Fas, and are sensitive to Fas ligand-induced PCD (Itoh et al., 1993) . Since Fas-mediated pathways to caspase activation and death are comparably well understood (Konopleva et al., 1999) , Pim-1 also was tested as a possible modulator of this more direct PCD pathway but proved ineective in repeated experiments (Pircher, Zhao, unpublished results).
Pim-1 does not substantially enhance cytokine-dependent FDCW2 cell growth, or c-myc transcript expression As introduced above, the ectopic expression of Pim-1 in at least certain hematopoietic cell lines can aect growth (Nosaka et al., 1999) . It was therefore important to test whether any such eects were exerted by exogenously expressed Pim-1 in FDCER-HY343F-Pim-1 cells. As illustrated by [ (Figure 7a, lower panel) . However, this increase was only 1 ± 3% of cytokine-induced rates and as mentioned above, mitogenesis (as assayed by direct cell counts) was not supported. For the Epo receptor form HY343F, signaling activity was con®rmed in experiments which demonstrated its ability to support Epo-stimulated c-myc transcription ( Figure  7b ). Thus, in contrast to eects on PCD, overall eects of Pim-1 on proliferation in this model system (and in 32D cells as well, Joneja, data not shown) were nominal. Finally, because Pim-1 has recently been reported to activate Cdc25a and therefore to possibly (Mochizuki et al., 1999) , levels of c-myc transcripts in Pim-1 expressing clones were also assayed by Northern blotting and phosphorimaging. However, the results of repeated independent experiments reproducibly showed c-myc transcript levels in these lines to be 40 ± 50% lower than levels in parental FDCER-HY343F cells (Pircher, unpublished) .
Discussion
Based on reports that Pim-1 can attenuate PCD as induced in hematopoietic progenitor cells by cytokine withdrawal (Lilly and Kraft, 1997; Lilly et al., 1999) or in B cells by dexamethasone (Moroy et al., 1993) , whether Pim-1 might also buer PCD in growing progenitor cells as induced by Co 60 or adriamycin was investigated. Speci®cally, an approach was developed by which factor dependent FDCW2 cells could be propagated at normal rates in the absence of endogenously expressed Pim-1. Here, endogenous cKit plus an exogenously expressed Epo receptor form lacking all cytoplasmic (P)Y sites proved to provide signals necessary and sucient for survival and mitogenesis, but not for Pim-1 gene transcription. This result reveals that the mitogenic synergy known to be exerted by SCF and Epo (Broudy, 1997) does not depend strictly either upon events associated with the recently described tyrosine phosphorylation of the Epo receptor by c-Kit (Wu et al., 1995) , or upon signals propagated via Epo phosphotyrosine sites per se. Mechanisms which support this novel route of synergy between c-Kit and ER-HY343F are under investigation. In addition, this result is consistent with the suggestion that STAT5 acts as a important activator of Pim-1 gene transcription (Mui et al., 1996; Rui et al., 1998) , and with the previous notion that Pim-1 transcription is not stimulated eciently by various RTKs, including c-Kit (Domen et al., 1993b) .
With speci®c regards to PCD, recent studies by Lilly et al. (1999) have documented that certain apoptotic events as induced by cytokine withdrawal are inhibited by the exogenous expression of Pim-1 in IL-3-dependent FDCP1 cells. This included the inhibition of PCD-associated decays in mitochondrial membrane potential, and of the production of reactive oxygen species. By comparison, studies by Mochizuki et al. (1997 Mochizuki et al. ( , 1999 of the eects of the forced co-expression of Pim-1 with either Cdc25a or c-Myc in Rat-1 ®broblasts have yielded somewhat disparate results. In this model, Pim-1 increased rates of Cdc25a-dependent transformation to anchorage-independent growth but also at the same time somewhat increased rates of PCD beyond those induced by the over-expression of these additional oncogenic factors. In the absence of overexpressed cdc25a or c-Myc, however, exogenous Pim-1 had little if any eect on either PCD or transforma- Figure 4 Ectopic expression of Pim-1 in proliferating FDCER-HY343F cells protects against PCD due to Co 60 and adriamycin. FDCER-HY343F cells or derived transfected lines ectopically expressing Pim-1 (FDCER-HY343F-Pim-1 (c7) and (c11)) were expanded in SCF plus Epo. Apoptotic sensitivities of growing cells to Co 60 (left panels) or adriamycin (right panels) then were assayed (PI positivity). Frequencies of PCD due to Co 60 were inhibited by Pim-1 on average 2.76-fold (+0.55) (n=four experiments), while PCD due to adriamycin was inhibited 2.37-fold (+0.61) (n=four experiments) tion (and Pim-1 is not normally expressed in this cell line model). Results of the present tests of eects of Pim-1 on PCD due to cytokine withdrawal in myeloid FDCW2 cells (as well as 32D cell lines) are in line with those by Lilly et al. (1999) as summarized above. In addition they illustrate the ability of Pim-1 to inhibit apoptosis as activated further by prior exposure to either Co 60 , or adriamycin (see Figure 2) , and provide the important novel result that as expressed in proliferating cells, Pim-1 also signi®cantly inhibits PCD due to either ionizing radiation or adriamycin (see Figures 4 ± 6). As mentioned above, ectopic expression of Pim-1 in lymphoid cells in Em-Pim-1 mice also previously has been shown to inhibit apoptosis as induced by dexamethasone (Moroy et al., 1993) . However, relatively little is understood concerning mechanisms of dexamethasone-induced death, and this eect of Pim-1 was observed only in a FAS-dependent lpr/lpr background.
The present ®ndings also raise certain additional questions regarding any mitogenic eects which Pim-1 might exert. In Pim-17/7 mice, no obvious defects in hematopoiesis are detected (van der Lugt et al., 1995) . This might be a consequence of compensation, yet in Em-Pim-1 transgenic mice numbers of B and T cells are likewise normal unless (as in approximately 10% of these mice) leukemic disease develops (van Lohuizen et al., 1989) . Presently, in FDCW2 cell lines no signi®cant eects on mitogenesis or cell cycle distributions were observed. This is in contrast to studies by Nosaka et al. (1999) in which Pim-1 expression in BaF/3 cells led to factor-independent growth. However, this was indicated to perhaps be a consequence of retroviral over- Indexed are relative levels of protection against apoptosis (survival) observed. Lower panel: In Western blot experiments M r 34 000 Pim-1 (but not M r 44 000 Pim-1) was discovered to occur in nuclear extracts. As markers, blots were stripped and probed for SH-PTP1B (cytoplasmic) and ERK1 and 2. Indexed by asterisks (*) are non-speci®c stained proteins, which also verify clear fractionation of nuclear vs cytoplasmic components Figure 5 Ectopic expression of Pim-1 in stably transfected FDCER-HY343F cells. Upper panel: Expression of exogenous Pim-1 transcripts in clonal lines stably co-transfected with pEFPim-1 and pAPuro. In this Northern blot screen for positive clones, cells were expanded in IL-3. Transcripts from pEF-Pim-1 resolve from larger endogenous Pim-1 transcripts. Center panel: Pim-1 protein expression in FDCER-HY343F-Pim-1 cells (clones 7 and 11) vs control parental FDCER-HY343F cells. Cells were expanded in the presence of SCF plus Epo and total cell lysates (50 ug per lane) were analysed by Western blotting. As a control a lysate from Cos 7 cells were transfected with pEF-Pim-1 was coanalysed. Lower panel: Also con®rmed was the ability of Pim-1 as expressed in FDCER-Hy343 cells to inhibit PCD due to cytokine withdrawal Oncogene Pim-1 inhibits genotoxin-induced PCD TJ Pircher et al expression and/or multiple integrations. Overall, these reports and the present ®ndings suggest that Pim-1 directly does not markedly aect mitogenesis.
In contrast, Pim-1 acts in proliferating hematopoietic progenitor cells to eciently inhibit PCD due to Co 60 , or adriamycin (see Figure 4) . The signi®cance of these results is underlined by the common use of these agents to treat cancers (Klein et al., 1985; Siu et al., 1999) and by the speculation that their eective doses against hematopoietic targets might be lessened if either Pim-1 or its co-acting factors could be inhibited. Despite intensive research, relatively little is understood as to how either ionizing radiation or anthracyclines link to apoptotic machinery (e.g., caspases). DNA damage by ionizing radiation is sensed by p53, PCNA, ATM, PARP, JNK, PKC, ceramides, ROS and possibly p73-alpha and c-Abl (Agami et al., 1999; Watters, 1999; Xu and Morris, 1999) . Adriamycin forms DNA adducts (Zeman et al., 1998) , inhibits several key enzymes (TopoII, RNA PolII), and likewise activates p53 and ROS production (Chuang and Chuang, 1979; Tewey et al., 1984) . Where Pim-1 might exert eects in these complex response pathways is unknown. In this context, Lilly et al. (1999) interestingly have reported that Pim-1 expression in FDCP1 cells leads to increases in Bcl-2 expression. In FDCW2 cells ectopically expressing Pim-1, however, no such eects were observed for Bcl-2 or Bcl-xL at either the transcript or protein level (Pircher, unpublished) . Finally, the present observation that M r 34 000 Pim-1 apparently translocates to the nucleus is notable for two reasons: Firstly, the prospect is provided that M r 34 000 Pim-1 might interact directly with several recently reported nuclear targets (Koike et al., 2000; Leverson et al., 1998; Mochizuki et al., 1999; Weston, 1999) . Secondly, no such nuclear compartmentalization was detected for M r 44 000 Pim-1 and this might at least provide an initial clue as to possible non-overlapping roles for these forms as produced from alternate CUG or ATG translation sites (Saris et al., 1991) .
Materials and methods
Epo receptor, Pim-1 and Bcl-xL expression vectors The Epo receptor form`H' is a previously described truncation mutant lacking residues 376 ± 483 (including seven of eight cytoplasmic (P)Y residues) (Quelle et al., 1996) . This receptor form was prepared by PCR using a BglII to ClaI Epo receptor cDNA fragment and the following primers: 5'-TGGTCCT-CATCTCGCTGTTGCTGA-3' and 5'-GCTCTAGACTAAG-CTTCATCCATAGTCACAGGGTCCAC-3'. This PCR product was cloned stepwise to pCRScript, to pSL1180wtER (BglII to XbaI), and to a dicistronic pMK10 59 vector (Koyayashi) (SpeI to XbaI). In the related Epo receptor form ERH-Y343F, a Y343 site was mutated to F343 using the above template and the following primers: 5'-GATCGGGCCCT-TACTGGGAGCCGGTGGGCAGTGAGCATGCCCAGG-ACACCTTCTTGGTATTGGATAAGTGG-3' and 5'GCTC-TAGA CTAAGCT TCATC CATA GTCAC AGGT CCAC-3'. The resulting PCR product was cloned to pSP72 as an ApaI to XbaI fragment, to pSL1180wtER (BglII to XbaI) and to pMK10 59 (SpeI to XbaI). All products were con®rmed by sequencing. The vector pEFNeo-Pim-1 was prepared by cloning a full-length murine Pim-1 cDNA to pEFNeo (Tsang et al., 1997) as a 1200 bp EcoRI to NotI fragment. pMK-Bcl-xL was prepared by cloning a 800 bp murine bcl-xL cDNA to pSL1180 at XbaI and XhoI sites, and pMC10 59 as a 800 bp SpeI to XbaI fragment.
Cell lines
pMK1059-ERY343 and -ERY343F constructs were electrotransfected into FDCW2 cells as described (Seshasayee et al., FDCW2-HY343F cells (or -HY343 cells as a control) were deprived of IL-3 for 10 h, and were then exposed to Epo (20 U/ ml). At the indicated intervals, RNA was isolated and c-myc transcript levels were assayed by Northern blotting. Also assayed were transcripts for endogenous Pim-1, exogenous Epo receptor forms, and gapdh H]dT was then added (1 mCi per assay) and at 2 h of incubation incorporated levels were determined (1205 Betaplate counter, KBL Pharmacia). Cell counts were performed in 0.1% Trypan blue in PBS (138 mM NaCl, 2.7 mM KCl, 1.2 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 pH 7.4). Alternatively, nonviable/apoptotic cells were assayed by staining with propidium iodide (PI) (5 mg/ml for 2 min) and¯ow cytometry (Coulter XL-MCL), or by TUNEL (TdT-mediated X-dUTP nick end labeling). In these assays, exponentially growing cells were adjusted to 3610 5 cells per ml, expanded to 8610 5 cells per ml, washed twice in Opti-MEM medium, and for cytokine withdrawal were then cultured at 5610 5 cells per ml in Opti-MEM medium, 1% FBS. Alternatively, cells at 4610 5 cells per ml were exposed to Co 60 (300 Rads) or adriamycin (0.025 ng/ml) and were cultured for 6 h prior to cytokine withdrawal. In TUNEL assays, fragmented DNA was labeled with biotin dNTPs (Trevigen FlowTACS TM Apoptosis Detection Kit) and was detected using FITCstreptavidin and¯ow cytometry. For assays of PCD in proliferating FDCER-HY343F-Pim-1 cells, cultures were initiated at 3610 5 cells per ml in Opti-MEM medium, 5% FBS, Epo (5 U/ml) and SCF (25 ng/ml). Cells then were exposed to Co 60 (600 Rads) or adriamycin (0.125 ng/ml) and at subsequent intervals were assayed for PCD.
Preparation of nuclear, and non-nuclear extract Cells were washed twice at 48C in 10 mM NaCl, 6 mM MgCl 2 , 10 mM Tris, pH 7.4 and incubated on ice for 20 min in 10 mM NaCl, 6 mM MgCl 2 , 1 mM dithiothreitol, 0.1% Triton X-100, 0.1 mM Na 3 VO 4 , 10 mM Tris, pH 7.4, containing 0.4 mM PMSF, 3 mg/ml aprotinin, 1 mg/ml pepstatin, 1 mg/ml leupeptin. Nuclei then were collected by microcentrifugation, and the 0.1% Triton-X soluble supernatant was recovered. Nuclei then were washed, and extracted for 30 min at 48C in 3 volumes of 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA 1 mM dithiothreitol, 0.1 mM Na 3 VO 4 , 20% glycerol, 20 mM HEPES, pH 7.9, containing 0.4 mM PMSF, 3 mg/ml aprotinin, 1 mg/ml pepstatin, and 1 mg/ml leupeptin. Samples then were centrifuged for 10 min at 8000 g and protein concentrations were adjusted to equivalence (Bradford reagent, Sigma) and stored at 7808C.
Abbreviations PCD, programmed cell death; S/T, serine/threonine; SCF, stem cell factor; EPO, erythropoietin; IL, interleukin; GM-CSF, granulocyte macrophage colony stimulating factor; Tpo, thrombopoietin; M r , molecular weight (relative mass); ER, erythropoietin receptor; TUNEL, TdT-mediated XdUTP nick end labeling; [ 3 H]dT, [methyl-3 H]thymidine; RTK, receptor tyrosine kinase; PCNA, proliferating cell nuclear antigen; ATM, ataxia-telangiectasia mutated; PARP, poly (ADP ribose) polymerase; JNK, c-jun Nterminal kinase; PKC, protein kinase C; ROS, reactive oxygen species; PKC, protein kinase C; PCR, polymerase chain reaction; FBS, fetal bovine serum; PBS, phosphate buer saline; PI, propidium iodide; FITC,¯uorescein isothiocyanate.
